Pharma

The dietary supplement and functional food markets are moving faster than ever. As consumers increasingly demand higher efficacy, cleaner labels, and faster absorption, traditional powder-filled capsules and standard compressed tablets are often no longer enough to make a brand stand out on a crowded shelf. Formulators and brand owners are continuously challenged to solve complex stability issues, enhance bioavailability, and deliver novel aesthetic experiences.

The dietary supplement and functional food markets are moving faster than ever. As consumers increasingly demand higher efficacy, cleaner labels, and faster absorption, traditional powder-filled capsules and standard compressed tablets are often no longer enough to make a brand stand out on a crowded shelf. Formulators and brand owners are continuously challenged to solve complex stability issues, enhance bioavailability, and deliver novel aesthetic experiences.

In recent years, the global pharmaceutical supply chain has faced unprecedented turbulence. From pandemic era logistics gridlock to regional conflicts and geopolitical shifts, sourcing raw materials and excipients has become a high-stakes challenge. In an industry where a single missing component can grind manufacturing to a halt, traditional “just-in-time” shipping models are no longer enough.

Navigating the landscape of pharmaceutical excipients is a masterclass in balancing scientific ambition with stringent regulatory realities. When industry discussions turn to innovation, the term “new excipient” is often thrown around loosely, but its practical definition is far more nuanced. As David Schoneker, president of Black Diamond Regulatory Consulting, points out, new excipients encompass everything from novel chemical entities (NCEs) and higher usage levels to new routes of administration, specialized patient populations, co-processed materials, and functional adaptations from the food and cosmetics industries.